Moderna : 2024 laying the foundations for 2025 and 2026
>2024 to set the tone for 2025 - We were pleased to accompany Stéphane Bancel, the CEO of Moderna, on a roadshow. The investor meeting was an opportunity to highlight the main stages for the company: i/ clinically, ii/regulatorily and iii/commercially. For respiratory vaccines, we particularly note the confirmed launch of 4 new mRNA out to end-2025: i/ respiratory syncytial virus (RSV), ii/ seasonal flu, iii/ a new version of COVID 19, and iv/ a flu/COVID 19 comb...Moderna is creating a new generation of medicines based on messenger RNA to improve the lives of patients. The company uses its platform to identify and develop new mRNA medicines. When the company identifies a combination of platform technologies or programs across mRNA technologies, delivery technologies, and manufacturing processes that can enable shared product features across multiple potential mRNA medicines, it groups those programs as a modality. The company has created six modalities including prohylactic vaccines; cancer vaccines; intratumoral immuno-oncology; localized regenerative therapeuctics; systemic secreted therapeutics; and systemic intracellular therapeutics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.